Drug Profile

AB 8939

Alternative Names: AB-8939

Latest Information Update: 19 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AB Science
Class Aniline compounds; Antineoplastics; Benzene derivatives; Ethers; Imidazolidines; Oxazoles; Small molecules; Toluenes
Mechanism of Action Aldehyde dehydrogenase inhibitors; Apoptosis stimulants; Tubulin polymerisation inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Acute myeloid leukaemia
New Molecular Entity Yes

Highest Development Phases

Phase I/II Acute myeloid leukaemia

Most Recent Events

08 Jan 2026 Efficacy and adverse event data from a phase I/II trial in Acute myeloid leukaemia released by AB Science
31 Oct 2025 Chemical structure information added.
17 Oct 2025 AB Science met with the US FDA and EMA to discuss next steps in the clinical development of AB 8939

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com